直击业绩会丨康方生物董事长夏瑜谈“明星”双抗产品:今年预计覆盖2000家医院,目前不适合给出业绩指引

每日经济新闻
31 Mar

“今年是我们进入医保的元年,(两款双抗药物)还在快速放量的过程中,在这样的前提下,我认为给业绩指引是不妥的。”在3月31日康方生物的业绩说明会上,当机构投资者希望公司给出两款核心双抗卡度尼利单抗和依沃西单抗的业绩指引时,康方生物董事长夏瑜如是表示。  根据康方生物最新披露的2024年业绩,公司实现收入21.24亿元,同比下降53.08%,毛利为18.35亿元,同比减少58.23%,亏损5.01亿元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10